Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $34.35 is 27.70% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 34.65||$ 42.95|
|Low:||$ 33||$ 26.90|
ETFs with XENT as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.93%||iShares U.S. Pharmaceutical ETF (IHE)||+5.22 (3.43%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. Our approved products are steroid releasing implants designed to treat the spectrum of needs among patients who are managed by ENT physicians for chronic sinusitis, one of the most prevalent chronic diseases in the United States and one of the most costly conditions for U.S. employers. We are currently marketing our PROPEL® family of products, consisting of PROPEL®, PROPEL® Mini and PROPEL® Contour, which are used following sinus surgery to deliver steroid locally to treat inflammation and improve surgical outcomes. In addition, we received FDA approval in December 2017 for our SINUVA(TM) Sinus Implant, a new targeted approach to treating nasal polyp disease in patients who have had previous ethmoid sinus surgery. ... More ...
Nasdaq Official Price
Jul. 17, 2018
Jul. 17, 2018